

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT					ATTORNEY'S DOCKET NO.: 16153-5587		
Applicant: William S. M. Wold		Serial No.: 09/111,911		Filing Date: 7/8/1998		Group Art Unit: 1632	
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number:	Date:	Name:	Class:	Sub- Class:	Filing Date:
	AA						
FOREIGN PATENT DOCUMENTS							
		Document Number:	Date:	Country:	Class:	Sub- Class:	Translation:
	AB						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, etc.)							
<i>GML</i>	AC	Carlin et al., Epidermal Growth Factor Receptor is Down-Regulated by a 10,400 MW Protein Encoded by the E3 Region of Adenovirus, <i>Cell</i> , 57:135-144 (1989)					
<i>GML</i>	AD	Clark et al., Molecular Pathways of CTL-mediated Cytotoxicity, <i>Immunological Reviews</i> , 146:33-44 (1995)					
<i>GML</i>	AE	Dimitrov et al., Adenovirus E3-10.4K/14.5K Protein Complex Inhibits Tumor Necrosis Factor-Induced Translocation of Cytosolic Phospholipase A ₂ to Membranes, <i>J. of Virol.</i> , 71:2830-2837 (1997)					
<i>GML</i>	AF	Efrat et al., Prolonged survival of pancreatic islet allografts mediated by adenovirus immunoregulatory transgenes, <i>Proc. Natl. Acad. Sci. USA</i> , 92:6947-6951 (1995)					
<i>GML</i>	AG	Fejer et al., Characterization of Transgenic Mice Containing Adenovirus Early Region 3 Genomic DNA, <i>J. of Virol.</i> , 68:5871-5881 (1994)					
<i>GML</i>	AH	French et al., Thyroiditis and hepatitis: Fas on the road to disease, <i>Nature Med.</i> , 3(4):387-388 (1997)					
<i>GML</i>	AI	Friesen et al., Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells, <i>Nature Med.</i> , 2(5):574-577 (1996)					
<i>GML</i>	AJ	Giordano et al., Potential Involvement of Fas and Its Ligand in the Pathogenesis of Hashimoto's Thyroiditis, <i>Science</i> , 275:960-963 (1997)					
<i>GML</i>	AK	Hahne et al., Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape, <i>Science</i> , 274:1363-1366 (1996)					
<i>GML</i>	AL	Hermiston et al., The Adenovirus E3-10.4K/14.5K Heterodimer, Renamed RID (Receptor Internalization and Degradation), Inhibits TNF-induced Apoptosis, Arachidonic Acid Release, Translocation of cPLA ₂ to Membranes, and Fas-induced Apoptosis, and it Down-regulates Cell Surface Fas and EGF Receptor, Abstract presented at Small DNA Tumor Viruses Meeting, July 9-14, 1996					
<i>GML</i>	AM	Hermiston et al., Deletion Mutation Analysis of the Adenovirus Type 2 E3-gp19K Protein: Identification of Sequences within the Endoplasmic Reticulum Luminal Domain That Are Required for Class I Antigen Binding and Protection from Adenovirus-Specific Cytotoxic T Lymphocytes, <i>Journal of Virology</i> , 67(9):5289-5298 (1993)					
<i>GML</i>	AN	Herrath et al., Expression of adenoviral E3 transgenes in β cells prevents autoimmune diabetes, <i>Proc. Natl. Acad. Sci. USA</i> , 94:9808-9813 (1997)					

BEST AVAILABLE COPY

GML	AO	Ilan et al., Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression, <i>Proc. Natl. Acad. Sci. USA</i> , 94:2587-2592 (1997)
GML	AP	Kondo et al., Essential roles of the Fas Ligand in the development of hepatitis, <i>Nature Medicine</i> , 3(4):409-413 (1997)
GML	AQ	Krajcsi et al., The Adenovirus E3-14.7K Protein and the E3-10.4K/14.5K Complex of Proteins, Which Independently Inhibit Tumor Necrosis Factor (TNF)-Induced Apoptosis, Also Independently Inhibit TNF-Induced Release of Arachidonic Acid, <i>J. of Virol.</i> , 70(8):4904-4913 (1996)
GML	AR	Lau et al., Prevention of Islet Allograft Rejection with Engineered Myoblasts Expressing FasL in Mice, <i>Science</i> , 273:109-112 (1996)
GML	AS	Lenardo, Fas and the Art of Lymphocyte Maintenance, <i>The Journal of Experimental Medicine</i> , 183:721-724 (1996)
GML	AT	Nagata, Fas ligand and immune evasion, <i>Nature Med.</i> , 2(12):1306-1307 (1996)
GML	AU	Nagata, Apoptosis by Death Factor, <i>Cell</i> , 88:355-365 (1997)
GML	AV	O'Connell et al., The Fas Counterattack: Fas-mediated T Cell Killing by Colon Cancer Cells Expressing Fas Ligand, <i>J. Exp. Med.</i> , 184:1075-1082 (1996)
GML	AW	Shisler et al., The Adenovirus E3-10.4K/14.5K Complex Mediates Loss of Cell Surface Fas (CD95) and Resistance to Fas-Induced Apoptosis, <i>J. of Virol.</i> , 71:8299-8306 (1997)
GML	AX	Sparer et al., The Role of Human Adenovirus Early Region 3 Proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a Murine Pneumonia Model, <i>J. of Virol.</i> , 70:2431-2439 (1996)
GML	AY	Stewart et al., The Adenovirus E3 10.4K and 14.5K Proteins, Which Function to Prevent Cytolysis by Tumor Necrosis Factor and To Down-Regulate the Epidermal Growth Factor Receptor, Are Localized in the Plasma Membrane, <i>J. of Virol.</i> , 69:172-181 (1995)
GML	AZ	Strand et al., Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion?, <i>Nature Medicine</i> , 2(12):1361-1366 (1996)
GML	BA	Tanaka et al., Fas ligand in human serum, <i>Nature Medicine</i> , 2(3): 317-322 (1996)
GML	BB	Tollefson et al., Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells, <i>Nature</i> , 392:726-730 (1998)
GML	BC	Tollefson et al., The 10,400- and 14,500-Dalton Proteins Encoded by Region E3 of Adenovirus Form a Complex and Function together to Down-Regulate the Epidermal Growth Factor Receptor, <i>J. of Virol.</i> , 65:3095-3105 (1991)
GML	BD	Williams, Tumor Cells Fight Back to Beat Immune System, <i>Science</i> , 274:1302 (1996)
GML	BE	Williams, Thyroid Disease: A Case of Cell Suicide?, <i>Science</i> , 275:926 (1997)
GML	BF	Wold, NIH Grant RO1 CA58538 pp. 1-2, 45-81 (Funded 7/18/97)

EXAMINER:

DATE CONSIDERED:

Gail M. Lee

12/3/99

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of the form with next communication to applicant.